MESO Q3 2017 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$901,000-78.2% YoY

Gross Profit

-$3M-325.1% margin

Operating Income

-$22M-2441.1% margin

Net Income

-$10M-1085.9% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+63.8%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$746,000

Balance Sheet

Total Assets

$679M

Total Liabilities

$139M

Stockholders' Equity

$540M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$901,000	$4M	-78.2%
Gross Profit	-$3M	-$4M	+18.2%
Operating Income	-$22M	-$20M	-7.5%
Net Income	-$10M	-$17M	+42.2%